Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 24 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 10450384

    Compositions of alpha-1 antitrypsin fusion molecules

    The Regents of the University of Colorado · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  2. US 10443052

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  3. US 10441590

    Methods for treating pulmonary hypertension

    REVIVA PHARMACEUTICALS, INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  4. US 10435695

    Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  5. US 10434188

    Hyaluronic acid binding domain-growth factor fusion protein cDNAs and fusion proteins for cartilage matrix preservation and repair

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  6. US 10428133

    Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted

  7. US 10428135

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted

  8. US 10421802

    Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted

  9. US 10422807

    Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

    PRECISION IBD, INC. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted

  10. US 10420813

    Competitive inhibitors of invariant chain expression and/or ectopic clip binding

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted

  11. US 10415015

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Iovance Biotherapeutics, Inc. · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  12. US 10415037

    Compositions and methods for silencing hepatitis B virus gene expression

    ARBUTUS BIOPHARMA CORPORATION · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  13. US 10415038

    Compounds and methods for modulating TMPRSS6 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  14. US 10413620

    Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  15. US 10406226

    Method of manufacturing VEGF antagonist fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted

  16. US 10407678

    Compositions for modulating expression of C9ORF72 antisense transcript

    Ionis Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted

  17. US 10407680

    Compounds and methods for reducing Tau expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted

  18. CA 3091946

    EXPANSION ET DIFFERENCIATION DE CELLULES SOUCHES

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Sep 6, 2019 · Expires Sep 1, 2039

    granted

  19. US 10400239

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  20. US 10400029

    Serpin fusion polypeptides and methods of use thereof

    Inhibrx, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  21. US 10391126

    CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA

    The Board of Regents of the University of Texas System · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted

  22. US 10383960

    Small molecule imaging of fungi by positron emission tomography scanning

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 20, 2019 · Expires Aug 15, 2039

    granted

  23. US 10376567

    Fusion molecule based on TAA variant

    The Regents of the University of California · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted

  24. US 10364433

    Modulation of AGPAT5 expression

    The Regents of the University of California · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.